Oncopeptides AB (publ) (LON:0RN4)

Oncopeptides AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	31.65	35.22	8.36	118.3	-
Revenue Growth (YoY)	-10.14%	321.54%	-92.94%	-	-
Cost of Revenue	2.66	-1.08	0.01	53.12	-
Gross Profit	28.99	36.3	8.35	65.17	-
Selling, General & Admin	197.28	188.48	142.2	873.81	654.19
Research & Development	121.19	106.95	217.66	679.93	866.21
Other Operating Expenses	-5.99	-6.34	-4.57	3.9	-
Operating Expenses	312.48	289.09	355.29	1,558	1,520
Operating Income	-283.5	-252.79	-346.94	-1,492	-1,520
Interest Expense	-0.71	-5.79	-0.88	-0.95	-1.49
Interest & Investment Income	-	8.59	2.62	0.49	0.32
Currency Exchange Gain (Loss)	-	1.54	8.96	71.54	-70.87
Other Non Operating Income (Expenses)	0	-	-	0	-
EBT Excluding Unusual Items	-284.21	-248.45	-336.24	-1,421	-1,592
Gain (Loss) on Sale of Assets	-	-	-1.44	-	-
Pretax Income	-284.21	-248.45	-337.68	-1,421	-1,592
Income Tax Expense	0.4	0.66	0.27	8.95	2.25
Net Income	-284.61	-249.11	-337.95	-1,430	-1,595
Net Income to Common	-284.61	-249.11	-337.95	-1,430	-1,595
Shares Outstanding (Basic)	166	90	82	75	62
Shares Outstanding (Diluted)	166	90	82	75	62
Shares Change (YoY)	84.13%	9.80%	9.33%	20.72%	20.63%
EPS (Basic)	-1.71	-2.76	-4.11	-19.00	-25.57
EPS (Diluted)	-1.71	-2.76	-4.11	-19.00	-25.57
Free Cash Flow	-260.57	-279.61	-423.02	-1,517	-1,314
Free Cash Flow Per Share	-1.57	-3.09	-5.14	-20.14	-21.06
Gross Margin	91.59%	103.06%	99.93%	55.09%	-
Operating Margin	-895.79%	-717.74%	-4152.44%	-1261.64%	-
Profit Margin	-899.29%	-707.30%	-4044.90%	-1209.11%	-
Free Cash Flow Margin	-823.34%	-793.89%	-5063.03%	-1282.16%	-
EBITDA	-281.06	-250.35	-344.93	-1,491	-1,519
D&A For EBITDA	2.44	2.44	2.01	1.72	1.72
EBIT	-283.5	-252.79	-346.94	-1,492	-1,520

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.